Non-small cell lung cancer (NSCLC) develops in lung tissues, but when it's metastatic, it has spread to distant areas of the ...

During a live event, Bruna Pellini, MD, discussed IO monotherapy as a first-line option for non–small cell lung cancer with ...

Tagrisso with chemo significantly improved survival and progression-free outcomes versus Tagrisso alone in newly diagnosed ...

Quality-of-life in lung cancer varies, with certain treatments leading to sleep-related issues, pain, and emotional changes ...

Non-Small Cell Lung Cancer Market grows as immunotherapy approvals by Merck & Bristol-Myers reshape global treatment pathways. Anurag Tiwari Orion Market Research Pvt Ltd +91 91798 28694 email us here ...

Medical experts report rising lung cancer diagnoses in non-smokers as smoking rates decline, raising questions about ...

AstraZeneca is raising its defenses against Johnson & Johnson in a fierce competition in EGFR-mutated non-small cell lung ...

AstraZeneca has bolstered the standing of Tagrisso as a first-line treatment for locally advanced or metastatic EGFR-mutated ...

Scientists have uncovered a molecular "on–off" switch that helps lung adenocarcinoma—the most common form of lung cancer—grow ...

Lung cancer, the second-most common cancer in the U.S., is often associated with smoking — but even those who have never had a cigarette could be at risk of the deadly disease.

Small cell lung cancer (SCLC) is a fast-growing cancer that forms in the lung. It's one of two types of lung cancer. The other type is non-small cell lung cancer (NSCLC). SCLC is less common than ...